| |  Online-Ressource |
|---|
| Verfasst von: | Groenendijk, Alissa [VerfasserIn]  |
|---|
| | van Tinteren, Harm [VerfasserIn] |
|---|
| | Jiang, Yilin [VerfasserIn] |
|---|
| | de Krijger, Ronald R. [VerfasserIn] |
|---|
| | Vujanic, Gordan M. [VerfasserIn] |
|---|
| | Godzinski, Jan [VerfasserIn] |
|---|
| | Rübe, Christian [VerfasserIn] |
|---|
| | Schenk, Jens-Peter [VerfasserIn] |
|---|
| | Morosi, Carlo [VerfasserIn] |
|---|
| | Pritchard-Jones, Kathy [VerfasserIn] |
|---|
| | Al-Saadi, Reem [VerfasserIn] |
|---|
| | Vaidya, Sucheta J. [VerfasserIn] |
|---|
| | Verschuur, Arnauld C. [VerfasserIn] |
|---|
| | Ramírez-Villar, Gema L. [VerfasserIn] |
|---|
| | Graf, Norbert [VerfasserIn] |
|---|
| | de Camargo, Beatriz [VerfasserIn] |
|---|
| | Drost, Jarno [VerfasserIn] |
|---|
| | Perotti, Daniela [VerfasserIn] |
|---|
| | van den Heuvel-Eibrink, Marry M. [VerfasserIn] |
|---|
| | Brok, Jesper [VerfasserIn] |
|---|
| | Spreafico, Filippo [VerfasserIn] |
|---|
| | Mavinkurve-Groothuis, Annelies M. C. [VerfasserIn] |
|---|
| Titel: | Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only |
|---|
| Titelzusatz: | the SIOP 93-01 and 2001 protocols |
|---|
| Verf.angabe: | Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 15 January 2022 |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Gesehen am 01.07.2022 |
|---|
| Titel Quelle: | Enthalten in: European journal of cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1992 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 163(2022) vom: März, Seite 88-97 |
|---|
| ISSN Quelle: | 1879-0852 |
|---|
| Abstract: | Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. |
|---|
| DOI: | doi:10.1016/j.ejca.2021.12.014 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.ejca.2021.12.014 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0959804921012855 |
|---|
| | DOI: https://doi.org/10.1016/j.ejca.2021.12.014 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Recurrence |
|---|
| | SIOP protocol |
|---|
| | Treatment outcome |
|---|
| | Wilms tumour |
|---|
| K10plus-PPN: | 1808744187 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only / Groenendijk, Alissa [VerfasserIn]; 15 January 2022 (Online-Ressource)
